However, other studies indicate higher HER2-positive status than in our cohort, increased programmed cell death ligand-1 (PDL1) positivity, and the presence of specific somatic tumor mutations and germline mutations like Breast Cancer susceptibility gen1 mutation [34,35,36,37,38]. The gene discussed is ERBB2; the disease is neoplasm.